LE-PODefree
patency, and MALEsurvival (93% vs 80%; P < .001) rates at
free survival were
1 year after procedure; OPAR was
compared
associated with lower hazard of
MALE (HR, 0.35; 95% CI, 0.15-0.86;
P < .05), MALE-POD (HR, 0